tiprankstipranks
Kyverna Therapeutics reports Q3 EPS (80c), consensus (79c)
PremiumThe FlyKyverna Therapeutics reports Q3 EPS (80c), consensus (79c)
8d ago
Premium
Company Announcements
Kyverna Therapeutics Strengthens Board with New Appointment
1M ago
Kyverna Therapeutics initiated with a Buy at UBS
Premium
The Fly
Kyverna Therapeutics initiated with a Buy at UBS
1M ago
Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
PremiumThe FlyKyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
2M ago
Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
Premium
The Fly
Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
3M ago
Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
Premium
The Fly
Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
3M ago
Kyverna RMAT designation positive for shares, says Leerink
PremiumThe FlyKyverna RMAT designation positive for shares, says Leerink
4M ago
Premium
Company Announcements
Kyverna Therapeutics’ KYV-101 Gains FDA Advanced Therapy Designation
4M ago
Kyverna Therapeutics’ KYV-101 granted FDA RMAT designation
Premium
The Fly
Kyverna Therapeutics’ KYV-101 granted FDA RMAT designation
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100